Danaher Co. (NYSE:DHR) Shares Sold by Riverbridge Partners LLC

Riverbridge Partners LLC trimmed its holdings in shares of Danaher Co. (NYSE:DHR) by 3.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 271,356 shares of the conglomerate’s stock after selling 9,577 shares during the period. Riverbridge Partners LLC’s holdings in Danaher were worth $62,290,000 at the end of the most recent reporting period.

Several other large investors also recently made changes to their positions in DHR. Decker Retirement Planning Inc. purchased a new stake in Danaher during the 4th quarter worth $31,000. Teachers Insurance & Annuity Association of America purchased a new stake in shares of Danaher in the third quarter worth about $39,000. MidAtlantic Capital Management Inc. acquired a new stake in shares of Danaher in the third quarter valued at about $40,000. FSA Wealth Management LLC purchased a new stake in shares of Danaher during the 3rd quarter valued at about $50,000. Finally, Darwin Wealth Management LLC acquired a new position in Danaher during the 3rd quarter worth approximately $55,000. Institutional investors and hedge funds own 79.05% of the company’s stock.

Danaher Price Performance

Shares of DHR opened at $244.19 on Thursday. The company has a market cap of $176.38 billion, a P/E ratio of 46.60, a PEG ratio of 4.43 and a beta of 0.83. The stock has a fifty day moving average price of $234.84 and a 200 day moving average price of $253.53. Danaher Co. has a 12 month low of $225.42 and a 12 month high of $281.70. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.37 and a quick ratio of 1.01.

Danaher (NYSE:DHR) last issued its quarterly earnings data on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share for the quarter, beating analysts’ consensus estimates of $1.57 by $0.14. Danaher had a net margin of 16.39% and a return on equity of 10.62%. The business had revenue of $5.80 billion for the quarter, compared to analysts’ expectations of $5.59 billion. During the same period in the previous year, the business earned $2.02 earnings per share. The company’s revenue was up 3.1% on a year-over-year basis. On average, research analysts forecast that Danaher Co. will post 7.5 earnings per share for the current year.

Danaher Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Friday, December 27th will be paid a $0.27 dividend. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.44%. The ex-dividend date is Friday, December 27th. Danaher’s dividend payout ratio is presently 20.61%.

Analysts Set New Price Targets

A number of research firms have recently issued reports on DHR. Guggenheim started coverage on shares of Danaher in a research note on Thursday, December 19th. They set a “buy” rating and a $275.00 price objective on the stock. Barclays dropped their price target on shares of Danaher from $285.00 to $275.00 and set an “equal weight” rating on the stock in a research note on Wednesday, October 23rd. Stephens reissued an “overweight” rating and issued a $315.00 price objective on shares of Danaher in a research report on Wednesday, October 23rd. KeyCorp boosted their price target on Danaher from $290.00 to $310.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 23rd. Finally, Robert W. Baird lowered their price objective on Danaher from $278.00 to $277.00 and set an “outperform” rating for the company in a research note on Wednesday, October 23rd. Six equities research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the stock. According to data from MarketBeat, Danaher currently has a consensus rating of “Moderate Buy” and an average price target of $285.55.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.